Table 3 Expression of GAGE, NY-ESO-1 and SP17 in different stages of NSCLC
Antigen | TNM stage | ||
|---|---|---|---|
Ia-b (n = 88) | II-IIIa (n = 81) | p-value | |
GAGE | 15 (17.0%) | 29 (35.8%) | 0.02 |
>1% - ≤ 10% | 4 (4.5%) | 6 (7.4%) | |
>10% - ≤ 50% | 0 | 6 (7.4%) | |
>50% | 11 (12.5%) | 17 (21.0%) | |
NY-ESO-1 | 9 (10.2%) | 11 (13.6%) | 0.36 |
>1% - ≤ 10% | 0 | 3 (3.7%) | |
>10% - ≤ 50% | 2 (2.3%) | 1 (1.2%) | |
>50% | 7 (7.9%) | 7 (8.7%) | |
SP17 | 4 (4.5%) | 4 (4.9%) | 0.94 |
>1% - ≤ 10% | 4 (4.5%) | 4 (4.9%) | |
>10% - ≤ 50% | 0 | 0 | |
>50% | 0 | 0 | |